The University of Chicago Medicine (UChicago Medicine) has initiated a Phase 2 clinical trial to explore the potential of CAR T-cell therapy in treating three challenging autoimmune diseases: systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis. CAR T-cell therapy, originally
A phase 1 clinical trial has brought new hope for patients with B-cell lymphoma, a type of blood cancer, through an innovative cell-based immunotherapy. Researchers from Washington University School of Medicine in St. Louis, along with other collaborators, have explored the safety and potential
Gene therapy, a revolutionary approach to treating and preventing diseases by modifying faulty genes, relies heavily on accurate measurement techniques. Ensuring the safety and efficacy of these treatments necessitates precise quantification of adeno-associated virus (AAV) vectors, which deliver
Adicet Bio is pioneering significant developments in its innovative CAR T-cell therapy, ADI-001, aimed at treating a range of autoimmune diseases. Among the targeted conditions are ANCA-associated vasculitis (AAV), systemic lupus erythematosus (SLE), and systemic sclerosis. Initially, patient
Aspect Biosystems, a pioneer in the field of bioprinted tissue therapeutics, recently closed a $115 million Series B financing round aimed at advancing its groundbreaking technology in regenerative medicine. This achievement, led by Dimension and supported by investors such as Novo Nordisk and
The Illinois Department of Healthcare and Family Services (HFS) has taken a significant step toward improving treatment access and affordability for Sickle Cell Disease (SCD) patients by issuing its first comprehensive report on gene and cell therapy treatments. This report, generated in
